A patient with hairy cell leukemia (HCL) may show disease progression after being treated. A patient with evidence for disease progression may require additional or novel therapy.
Criteria for disease progression:
(1) an increase in symptoms related to disease (fatigue, frequent infection, other)
(2) >= 25% decline in hematologic parameters
(3) >= 25% increase in organomegaly (relative to nadir measurements after therapy)
The diagnosis of progression requires exclusion of:
(1) therapy-related myelosuppression
(2) therapy-related immunosuppression
To read more or access our algorithms and calculators, please log in or register.
